🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationCompounded sema potency testing — what worked for you?

Compounded sema potency testing — what worked for you?

Dr.PathRoch Thu, Aug 7, 2025 at 8:38 PM 13 replies 1,517 viewsPage 1 of 3
This thread is more than 10 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Aug 7, 2025 at 8:38 PM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

The question I want answered is why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission.

I have searched first, so if this is covered somewhere point me at it and I will read it.

27 5MikeFit_NJ, InsuranceTom, WendyG_ATL and 24 others
Reply Quote Save Share Report
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Aug 7, 2025 at 8:56 PM#2

Taking the question as asked, rather than the general version of it. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

28 6NurseKim_ATL, paul_denver, TinaHashiRN and 25 others
Reply Quote Save Share Report
MeganSA_TX
Member
634
2,890
Jun 2024
San Antonio, TX
Aug 7, 2025 at 9:14 PM#3
SarahChen_PharmD said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Agreeing with SarahChen_PharmD, and the qualification matters more than the agreement. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

29 7JessicaM_2024, TomFromTexas, mike.trainer_LA and 26 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
GraceAZ_72
Member
156
678
Jan 2025
Tucson, AZ
Aug 7, 2025 at 9:32 PM#4
Dr.PathRoch said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Same position here, arrived at the long way round. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

30 8JenPlateau, SallyK_inj, CryptoCarl and 27 others
Reply Quote Save Share Report
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Aug 7, 2025 at 11:08 PM#5

Adding the clinical framing, because it changes how the question reads.

Compounded has been just as effective for me. If compounded supply is the concern, the COA from my 503B pharmacy shows 99.1% purity. Verified by Janoshik.

31 9rachel_ABQ, traveltech_sara, AttorneyGrant and 28 others
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register